KOD250117C12500
- 0.10
- -0.20-66.67%
Kodiak Sciences Newsroom
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Crude Oil Surges 2%; Tesla Shares Plummet
Institutional Investors Have a Lot Riding on Kodiak Sciences Inc. (NASDAQ:KOD) With 43% Ownership
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases
12 Health Care Stocks Moving In Monday's Pre-Market Session
Sector Update: Health Care Stocks Edge Higher Monday Afternoon
Top Midday Gainers
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock
Kodiak Sciences Shares Soar After Upgrade From Jefferies
Jefferies Upgrades Kodiak Sciences(KOD.US) to Buy Rating, Raises Target Price to $20
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Cautious Approach: Kodiak Sciences' Retinal Pipeline Progress and Hold Rating
HC Wainwright & Co. Reiterates Neutral on Kodiak Sciences, Maintains $3 Price Target
Kodiak Sciences Analyst Ratings
Barclays Maintains Kodiak Sciences(KOD.US) With Sell Rating, Raises Target Price to $4
Barclays Remains a Sell on Kodiak Sciences (KOD)